GENFIT will advance the development of GFT505 after two Phase IIa trials successful demonstrated the drug’s ability to treat the symptoms of pre-diabetes.

The first study involved 47 patients with the condition, and found GFT505 caused significant reductions in fasting plasma glucose, fasting plasma insulin, and improvement of the HOMA insulin resistance index, compared to a placebo.

In the second study, involving 98 patients with atherogenic dyslipidaemia, researchers reported a 21% reduction in triglycerides and a 9% increase in high-density lipoprotein cholesterol.

GFT505 also reduced two indicators of liver dysfunction – alanine amino transferase and gamma glutamyl transpeptidase – without affecting the plasma level of aspartate amino transferase.